Legal highs: Staying on top of the flood of novel psychoactive substances

Therapeutic Advances in Psychopharmacology

Volumn 5, Issue 2, 2015, Pages 97-132

  Baumeister, David ^a   Tojo, Luis M ^a   Tracy, Derek K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

legal highs; novel psychoactive substances

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABIS; COCAINE; ENDOCANNABINOID; KETAMINE; LYSERGIDE; MONOAMINE; PHENCYCLIDINE; PSILOCYBINE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT;

DRUG DEPENDENCE; HUMAN; INTOXICATION; NEUROIMAGING; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84998035296     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125314559539     Document Type: Review

References (254)

1. Aarde S. Angrish D. Barlow D. Wright M. Vandewater S. Creehan K. et al. (2013) Mephedrone (4-Methylmethcathinone) Supports Intravenous Self-Administration in Sprague–Dawley and Wistar Rats. Addict Biol 18: 786–799.
2. Acuña-Castillo C. Villalobos C. Moya P. Saez P. Cassels B. Huidobro-Toro J. (2002) Differences in Potency and Efficacy of a Series of Phenylisopropylamine/Phenylethylamine Pairs at 5-HT(2a) and 5-HT(2c) Receptors. Br J Pharmacol 136: 510–519.
3. Allsop D.J. Copeland J. Lintzeris N. Dunlop A.J. Montebello M. Sadler C. et al. (2014) Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. J Am Med Assoc psychiatry 71: 281–291.
4. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association.
5. Angoa–Pérez M. Kane M.J. Francescutti D.M. Sykes K.E. Shah M.M. Mohammed A.M. et al. (2012) Mephedrone, an Abused Psychoactive Component of 'Bath Salts' and Methamphetamine Congener, Does Not Cause Neurotoxicity to Dopamine Nerve Endings of the Striatum. J Neurochem 120: 1097–1107.
6. Angoa–Pérez M. Kane M.J. Herrera–Mundo N. Francescutti D.M. Kuhn D.M. (2014) Effects of Combined Treatment with Mephedrone and Methamphetamine or 3,4–Methylenedioxymethamphetamine on Serotonin Nerve Endings of the Hippocampus. Life Sci 97: 31–36.
7. Atwood B.K. Huffman J. Straiker A. Mackie K. (2010) JWH018, a Common Constituent of 'Spice' Herbal Blends, Is a Potent and Efficacious Cannabinoid CB 1 Receptor Agonist. Br J Pharmacol 160: 585–593.
8. Ayorech Z. Tracy D.K. Baumeister D. Giaroli G. (2015) Taking the Fuel Out of the Fire: Evidence for the Use of Anti-Inflammatory Agents in the Treatment of Bipolar Disorders. J Affect Disord 174: 467–478. doi:10.1016/j.jad.2014.12.015.
9. Baumeister D. Barnes G. Giaroli G. Tracy D. (2014a) Classical Hallucinogens as Antidepressants? A Review of Pharmacodynamics and Putative Clinical Roles. Ther Adv Psychopharmacol 4: 156–169.
10. Baumeister D. Lightman S.L. Pariante C.M. (2014b) The Interface of Stress and the HPA Axis in Behavioural Phenotypes of Mental Illness. Curr Top Behav Neurosci. [Epub ahead of print]
11. Baumeister D. Russell A. Pariante C.M. Mondelli V. (2014c) Inflammatory Biomarker Profiles of Mental Disorders and Their Relation to Clinical, Social and Lifestyle Factors. Soc Psychiatry Psychiatr Epidemiol 49: 841–849.
12. Beck O. Rausberg L. Al–Saffar Y. Villen T. Karlsson L. Hansson T. et al. (2014) Detectability of new psychoactive substances, ‘legal highs’, in CEDIA, EMIT and KIMS immunochemical screening assays for drugs of abuse. Drug Test Anal 6: 492–499.
13. Becker A. Peters B. Schroeder H. Mann T. Huether G. Grecksch G. (2003) Ketamine-Induced Changes in Rat Behaviour: A Possible Animal Model of Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 4: 687–700.
14. Bedi G. Phan K.L. Angstadt M. De Wit H. (2009) Effects of MDMA on Sociability and Neural Response to Social Threat and Social Reward. Psychopharmacology 207: 73–83.
15. Berman S.M. Kuczenski R. McCracken J.T. London E.D. (2008) Potential Adverse Effects of Amphetamine Treatment on Brain and Behavior: A Review. Mol Psychiatry 14: 123.
16. Bersani F.S. Corazza O. Simonato P. Mylokosta A. Levari E. Lovaste R. et al. (2013) Drops of Madness? Recreational Misuse of Tropicamide Collyrium; Early Warning Alerts from Russia and Italy. Gen Hosp Psychiatry 35: 571–573.
17. Bhattacharyya S. Atakan Z. Martin-Santos R. Crippa J. McGuire P. (2012) Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man: A Critical Review of Neuroimaging Studies. Curr Pharm Des 18: 5045–5054.
18. Bhattacharyya S. Crippa J.A. Martin–Santos R. Winton–Brown T. Fusar–Poli P. (2009) Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology. Curr Pharm Des 15: 2603–2614.
19. Bhattacharyya S. Morrison P.D. Fusar–Poli P. Martin–Santos R. Borgwardt S. Winton–Brown T. et al. (2010) Opposite Effects of Delta–9–Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. Neuropsychopharmacology 35: 764–774.
20. Bornovalova M.A. Daughters S.B. Hernandez G.D. Richards J.B. Lejuez C.W. (2005) Differences in Impulsivity and Risk–Taking Propensity between Primary Users of Crack Cocaine and Primary Users of Heroin in a Residential Substance–Use Program. Exp Clin Psychopharmacol 13: 311–318.
21. Bosak A. Lovecchio F. Levine M. (2013) Recurrent Seizures and Serotonin Syndrome Following ‘2C–I’ Ingestion. J Med Toxicol 9: 196–198.
22. Bouso J.C. González D. Fondevila S. Cutchet M. Fernández X. Ribeiro Barbosa P.C. et al. (2012) Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study. PLoS ONE 7(8): e42421.
23. Boyer E.W. Shannon M. (2005) The Serotonin Syndrome. N Engl J Med 352: 1112–1120.
24. Braida D. Limonta V. Malabarba L. Zani A. Sala M. (2007) 5–HT1a Receptors Are Involved in the Anxiolytic Effect of Δ9–Tetrahydrocannabinol and AM 404, the Anandamide Transport Inhibitor, in Sprague–Dawley Rats. Eur J Pharmacol 555: 156–163.
25. Brewer T.L. Collins M. (2014) A Review of Clinical Manifestations in Adolescent and Young Adults after Use of Synthetic Cannabinoids. J Spec Pediatr Nurs 19: 119–126.
26. Butler G.K.L. Montgomery A.M.J. (2004) Impulsivity, Risk Taking and Recreational 'Ecstasy' (MDMA) Use. Drug Alcohol Depend 76: 55–62.
27. Caddy C. Giaroli G. White T.P. Shergill S.S. Tracy D.K. (2014) Ketamine as the Prototype Glutamatergic Antidepressant: Pharmacodynamic Actions and a Systematic Review and Meta–Analysis of Efficacy. Ther Adv Psychopharmacol 4: 75–99.
28. Carhart–Harris R. Erritzoe D. Williams T. Stone J. Reed L. Colasanti A. et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA 109: 2138–2143.
29. Carhart-Harris R.L. King L.A. Nutt D.J. (2011) A Web–Based Survey on Mephedrone. Drug Alcohol Depend 118: 19–22.
30. Carhart-Harris R.L. Leech R. Erritzoe D. Williams T.M. Stone J.M. Evans J. et al. (2013) Functional Connectivity Measures after Psilocybin Inform a Novel Hypothesis of Early Psychosis. Schizophr Bull 39: 1343–1351.
31. Carhart-Harris R.L. Murphy K. Leech R. Erritzoe D. Wall M.B. Ferguson B. et al. (2014) The Effects of Acutely Administered 3,4–Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity. Biol Psychiatry, in press.
32. Carrus D. Schifano F. (2012) Pregabalin Misuse–Related Issues; Intake of Large Dosages, Drug–Smoking Allegations and Possible Association with Myositis: Two Case Reports. J Clin Psychopharmacol 32: 839–840.
33. Chadwick B. Miller M.L. Hurd Y.L. (2013) Cannabis Use During Adolescent Development: Susceptibility to Psychiatric Illness. Front Psychiatry 4: 129.
34. Cheng J.Y.K. Chan D.T.W. Mok V.K.K. (2005) An Epidemiological Study on Alcohol/Drugs Related Fatal Traffic Crash Cases of Deceased Drivers in Hong Kong between 1996 and 2000. Forensic Sci Int 153: 196–201.
35. Chu P.S.K. Ma W.K. Wong S.C.W. Chu R.W.H. Cheng C.H. Wong S. et al. (2008) The Destruction of the Lower Urinary Tract by Ketamine Abuse: A New Syndrome? BrJ Urol Int 102: 1616–1622.
36. Coppola M. Mondola R. (2012) Methoxetamine: From Drug of Abuse to Rapid–Acting Antidepressant. Med Hypotheses 79: 504–507.
37. Corkery J.M. Durkin E. Elliott S. Schifano F. Ghodse A.H. (2012a) The Recreational Tryptamine 5–Meo–Dalt (N, N–Diallyl–5–Methoxytryptamine): A Brief Review. Prog Neuropsychopharmacol Biol Psychiatry 39: 259–262.
38. Corkery J.M. Schifano F. Ghodse A.H. (2012b) Phenazepam Abuse in the UK: An Emerging Problem Causing Serious Adverse Health Problems, Including Death. Hum Psychopharmacol 27: 254–261
39. Critchlow D. (2006). A case of ketamine dependence with discontinuation symptoms. Addiction 101: 1212–1213.
40. Cruickshank C.C. Dyer K.R. (2009) A Review of the Clinical Pharmacology of Methamphetamine. Addiction 104: 1085–1099.
41. Dantzer R. O'Connor J.C. Freund G.G. Johnson R.W. Kelley K.W. (2008) From Inflammation to Sickness and Depression: When the Immune System Subjugates the Brain. Nat Rev Neurosci 9: 46–56.
42. Dargan P.I. Albert S. Wood D.M. (2010) Mephedrone Use and Associated Adverse Effects in School and College/University Students before the UK Legislation Change. QJM 103: 875–879.
43. Dargan P.I. Davies S. Puchnarewicz M. Johnston A. Wood D.M. (2012) First Reported Case in the UK of Acute Prolonged Neuropsychiatric Toxicity Associated with Analytically Confirmed Recreational Use of Phenazepam. Eur J Clin Pharmacol 3: 361–363.
44. Dargan P.I. Davies S. Puchnarewicz M. Johnston A. Wood D.M. (2013) First Reported Case in the Uk of Acute Prolonged Neuropsychiatric Toxicity Associated with Analytically Confirmed Recreational Use of Phenazepam. Eur J Clin Pharmacol 69: 361–363.
45. Dargan P.I. Hudson S. Ramsey J. Wood D.M. (2011) The Impact of Changes in UK Classification of the Synthetic Cannabinoid Receptor Agonists in ‘Spice’. Int J Drug Policy 22: 274–277.
46. Dargan P.I. Tang H.C. Liang W. Wood D.M. Yew D.T. (2014) Three Months of Methoxetamine Administration Is Associated with Significant Bladder and Renal Toxicity in Mice. Clin Toxicol, 52: 176–180.
47. Dell'osso B. Lader M. (2013) Do Benzodiazepines Still Deserve a Major Role in the Treatment of Psychiatric Disorders? A Critical Reappraisal, Eur Psychiatry 28: 7–20
48. Den Hollander B. Rozov S. Linden A.M. Uusi–Oukari M. Ojanperä I. Korpi E.R. (2013) Long–Term Cognitive and Neurochemical Effects of ‘Bath Salt’ Designer Drugs Methylone and Mephedrone. Pharmacol Biochem Behav 103: 501–509.
49. Dick D. Torrance C. (2010) MixMag drugs survey. MixMag 44–53.
50. Dickson A.J. Vorce S.P. Levine B. Past M.R. (2010) Multiple–Drug Toxicity Caused by the Coadministration of 4–Methylmethcathinone (Mephedrone) and Heroin. J Anal Toxicol 34: 162–168.
51. Dillon P. Copeland J. Jansen K. (2003) Patterns of Use and Harms Associated with Non–Medical Ketamine Use. Drug Alcohol Depend 69: 23–28.
52. Doblin R. Greer G. Holland J. Jerome L. Mithoefer M.C. Sessa B. (2014) A Reconsideration and Response to Parrott AC (2013) ‘Human Psychobiology of MDMA or 'Ecstasy': An Overview of 25 Years of Empirical Research’. Hum Psychopharmacol 29: 105–108
53. Domino E.F. Chodoff P. Corssen G. (1965). Pharmacological effects of CI–581, a new dissociative anesthetic in man. Clin Pharmacol Ther 6: 279–291.
54. Drees J.C. Stone J.A. Wu A.H.B. (2009) Morbidity Involving the Hallucinogenic Designer Amines MDA and 2C–I. J Forensic Sci 54: 1485–1487.
55. Dumont G.J.H. Sweep F.C.G.J. Van Der Steen R. Hermsen R. Donders A.R.T. Touw D.J. et al. (2009) Increased Oxytocin Concentrations and Prosocial Feelings in Humans after Ecstasy (3,4–Methylenedioxymethamphetamine) Administration. Soc Neurosci 4: 359–366.
56. Durieux M.E. (1995) Inhibition by Ketamine of Muscarinic Acetylcholine Receptor Function. Anesth Analg 81: 57–62.
57. Elliott S. Evans J. (2014) A 3-Year Review of New Psychoactive Substances in Casework. Forensic Sci Int 243: 55–60.
58. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014a) European Drug Report 2014: Trends and developments. Lisbon: EMCDDA.
59. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014b) Risk Assessment Report of a new psychoactive substance: 2–(3–methoxyphenyl)–2–(ethylamino)cyclohexanone (methoxetamine). http://www.emcdda.europa.eu/publications/risk–assessment/methoxetamine (accessed on 19 June 2014).
60. Fantegrossi W.E. Moran J.H. Radominska–Pandya A. Prather P.L. (2014) Distinct Pharmacology and Metabolism of K2 Synthetic Cannabinoids Compared To Δ9–THC: Mechanism Underlying Greater Toxicity? Life Sci 97: 45–54.
61. Fleckenstein A.E. Gibb J.W. Hanson G.R. (2000) Differential Effects of Stimulants on Monoaminergic Transporters: Pharmacological Consequences and Implications for Neurotoxicity. Eur J Pharmacol 406: 1–13
62. Fleckenstein A.E. Volz T.J. Riddle E.L. Gibb J.W. Hanson G.R. (2007) New Insights into the Mechanism of Action of Amphetamines. Annu Rev Pharmacol Toxicol 47: 681–698.
63. Follesa P. Cagetti E. Mancuso L. Biggio F. Manca A. Maciocco E. et al. (2001) Increase in Expression of the GABA(a) Receptor Alpha(4) Subunit Gene Induced by Withdrawal of, but Not by Long–Term Treatment with, Benzodiazepine Full or Partial Agonists. Brain Res Mol Brain Res 92: 138–148.
64. Furuya R. Oka K. Watanabe I. Kamiya Y. Itoh H. Andoh T. (1999) The Effects of Ketamine and Propofol on Neuronal Nicotinic Acetylcholine Receptors and P2X Purinoceptors in PC12 Cells. Anesth Analg 88: 174–180.
65. Gamma A. Ph D. Buck A. Berthold T. Hell D. Vollenweider F.X. (2000) (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H 215 O] –PET in Healthy Humans. Neuropharmacology 23: 388–395.
66. Garcia L.S.B. Comim C.M. Valvassori S.S. Réus G.Z. Barbosa L.M. andreazza A.C. et al. (2008) Acute Administration of Ketamine Induces Antidepressant–Like Effects in the Forced Swimming Test and Increases BDNF Levels in the Rat Hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32: 140–144.
67. Gardner E.L. (2005) Endocannabinoid Signaling System and Brain Reward: Emphasis on Dopamine. Pharmacol Biochem Behav 81: 263–284.
68. Gee P. Richardson S. Woltersdorf W. Moore G. (2005) Toxic Effects of BZP–Based Herbal Party Pills in Humans: A Prospective Study in Christchurch, New Zealand. N Z Med J 118(1227): U1784.
69. Geneste P. Kamenka J. M. Ung J. M. Herrmann P. Goudal R. Trouiller G. (1979). Conformational determination of phencyclidine derivatives in view of structure–activity correlation. Eur J Med Chem 14: 301.
70. Gouzoulis–Mayfrank E. Thelen B. Habermeyer E. Kunert H.J. Kovar K.-A. Lindenblatt H. et al. (1999) Psychopathological, Neuroendocrine and Autonomic Effects of 3,4–Methylenedioxyethylamphetamine (MDE), Psilocybin and D–Methamphetamine in Healthy Volunteers. Psychopharmacology 142: 41–50.
71. Gray N. Cheng B. (1989) EU Patent No. EP0346791. Munich, Germany: European Patent Register.
72. Green S.M. Clark R. Hostetler M.A. Cohen M. Carlson D. Rothrock S.G. (1999) Inadvertent Ketamine Overdose in Children: Clinical Manifestations and Outcome. Ann Emerg Med 34: 492–497.
73. Greene S.L. Kerr F. Braitberg G. (2008) Review Article: Amphetamines and Related Drugs of Abuse. Emergency Med Australasia 20: 391–402.
74. Greer G. R. Tolbert R. (1998). A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 4: 371–379.
75. Gregg R.A. Rawls S.M. (2014) Behavioral Pharmacology of Designer Cathinones: A Review of the Preclinical Literature. Life Sci 97: 27–30
76. Griffiths R.R. Richards W.A. McCann U. Jesse R. (2006) Psilocybin Can Occasion Mystical–Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance. Psychopharmacology 187: 268–283.
77. Gunderson E.W. Haughey H.M. Ait–Daoud N. Joshi A.S. Hart C.L. (2012) ‘Spice’ and ‘K2’ Herbal Highs: A Case Series and Systematic Review of the Clinical Effects and Biopsychosocial Implications of Synthetic Cannabinoid Use in Humans. Am J Addict 21: 320–326.
78. Gurney S.M.R. Scott K.S. Kacinko S.L. Presley B.C. Logan B.K. (2014) Pharmacology, Toxicology and Adverse Effects of Synthetic Cannabinoid Drugs. Forensic Sci Rev 26: 54–76.
79. Halberstadt A.L. Geyer M.A. (2013) Serotonergic Hallucinogens as Translational Models Relevant to Schizophrenia. Int J Neuropsychopharmacol 16: 2165–2180.
80. Halberstadt A.L. Geyer M.A. (2014) Effects of the Hallucinogen 2,5–Dimethoxy–4–Iodophenethylamine (2C–I) and Superpotent N–Benzyl Derivatives on the Head Twitch Response. Neuropharmacology 77: 200–207.
81. Halpern J.H. Pope H.G. (2003) Hallucinogen Persisting Perception Disorder: What Do We Know after 50 Years? Drug Alcohol Depend 69: 109–119.
82. Harris C.R. Brown A. (2013) Synthetic Cannabinoid Intoxication: A Case Series and Review. J Emerg Med 44: 360–366
83. Harris D.S. Baggott M. Mendelson J.H. Mendelson J.E. Jones R.T. (2002) Subjective and Hormonal Effects of 3,4–Methylenedioxymethamphetamine (MDMA) in Humans. Psychopharmacology 162: 396–405.
84. Hasler F. Bourquin D. Brenneisen R. Bär T. Vollenweider F.X. (1997) Determination of Psilocin and 4–Hydroxyindole–3–Acetic Acid in Plasma by HPLC–ECD and Pharmacokinetic Profiles of Oral and Intravenous Psilocybin in Man. Pharm Acta Helv 72: 175–184.
85. Hasler F. Grimberg U. Benz M.A. Huber T. Vollenweider F.X. (2004) Acute Psychological and Physiological Affects of Psilocybin in Healthy Humans: A Double–Blind, Placebo–Controlled Dose–Effect Study. Psychopharmacology 172: 145–156.
86. Hayashi T. Tsai S.-Y. Mori T. Fujimoto M. Su T.-P. (2011) Targeting Ligand–Operated Chaperone Sigma–1 Receptors in the Treatment of Neuropsychiatric Disorders. Expert Opin Ther Targets 15: 557–577.
87. Hendricks P.S. Clark C.B. Johnson M.W. Fontaine K.R. Cropsey K.L. (2014) Hallucinogen Use Predicts Reduced Recidivism among Substance-Involved Offenders under Community Corrections Supervision. J Psychopharmacol 28: 62–66.
88. Hendricks P. Thorne C. Clark C. Coombs D. Johnson M. (in press) Classic Psychedelic Use is Associated with Reduced Psychological Distress and Suicidality in the United States Adult Population. J Psychopharmacol.
89. Herrling P. L. (1997). Excitatory Amino Acids: Clinical Results with Antagonists. New York: Academic Press
90. Hester J.B. Von Voigtlander P. (1979) 6–Aryl–4H–S–Triazolo[4,3–A][1,4]Benzodiazepines. Influence of 1–Substitution on Pharmacological Activity. J Med Chem 22: 1390–1398.
91. Hill M.N. Gorzalka B.B. (2004) Enhancement of Anxiety–Like Responsiveness to the Cannabinoid CB 1 Receptor Agonist HU–210 Following Chronic Stress. Eur J Pharmacol 499: 291–295.
92. Hill M.N. Tasker J.G. (2012) Endocannabinoid Signaling, Glucocorticoid–Mediated Negative Feedback and Regulation of the Hypothalamic–Pituitary–Adrenal Axis, Neuroscience 204: 5–16
93. Hill S.L. Doris T. Gurung S. Katebe S. Lomas A. Dunn M. et al. (2013) Severe Clinical Toxicity Associated with Analytically Confirmed Recreational Use of 25I–Nbome: Case Series. Clin Toxicol 51: 487–492.
94. Hofer K.E. Grager B. Müller D.M. Rauber–Lüthy C. Kupferschmidt H. Rentsch K.M. et al. (2012) Ketamine–Like Effects after Recreational Use of Methoxetamine. Ann Emerg Med 60: 97–99.
95. Hunault C.C. Böcker K.B.E. Stellato R.K. Kenemans J.L. De Vries I. Meulenbelt J. (2014) Acute Subjective Effects after Smoking Joints Containing up to 69 Mg Δ9–Tetrahydrocannabinol in Recreational Users: A Randomized, Crossover Clinical Trial. Psychopharmacology 2014; 231(24): 4723–33.
96. Hurst D. Loeffler G. McLay R. (2011). Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168: 1119.
97. Hustveit O. Maurset A. Oye I. (1995). Interaction of the chiral forms of ketamine with opioid, phencyclidine and muscarinic receptors. Pharmacol Toxicol 77: 355–359.
98. Huxley A. (1954). The Doors of Perception. 1st edn. New York: Harper.
99. Hysek C.M. Domes G. Liechti M.E. (2012) MDMA Enhances ‘Mind Reading’ of Positive Emotions and Impairs ‘Mind Reading’ of Negative Emotions. Psychopharmacology 222: 293–302.
100. Hysek C.M. Schmid Y. Simmler L.D. Domes G. Heinrichs M. Eisenegger C. et al. (2013) Mdma Enhances Emotional Empathy and Prosocial Behavior. Soc Cogn Affect Neurosci 222: 293–302.
101. Hysek C.M. Simmler L.D. Ineichen M. Grouzmann E. Hoener M.C. Brenneisen R. et al. (2011) The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (‘Ecstasy’) in Humans. Clin Pharmacol Ther 90: 246–255.
102. Ibrahim L. Diazgranados N. Franco–Chaves J. Brutsche N. Henter I.D. Kronstein P. et al. (2012) Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add–on Riluzole: Results from a 4–Week, Double–Blind, Placebo–Controlled Study. Neuropsychopharmacology 37: 1526–1533.
103. Iversen L. Gibbons S. Treble R. Setola V. Huang X.P. Roth B.L. (2013) Neurochemical Profiles of Some Novel Psychoactive Substances. Eur J Pharmacol 700: 147–151.
104. Jansen K.L. (2000). A Review of the Nonmedical Use of Ketamine: Use, Users and Consequences. J Psychoactive Drugs 32(4): 419–433.
105. Jebadurai J. Schifano F. Deluca P. (2013) Recreational Use of 1–(2–Naphthyl)–2–(1–Pyrrolidinyl)–1–Pentanone Hydrochloride (NRG–1), 6–(2–Aminopropyl) Benzofuran (Benzofury/ 6–APB) and NRG–2 with Review of Available Evidence–Based Literature. Hum Psychopharmacol 28: 356–364.
106. Jerome L. (2007). Psilocybin Investigator's Brochure. Multidisciplinary Association for Psychedelic Studies. Available at: http://www.maps.org/research/psilo/psilo_ib.pdf (accessed 3 December 2013).
107. Jerome L. (2008). D–Lysergic Acid Diethylamide (LSD) Investigator's Brochure. Multidisciplinary Association for Psychedelic Studies. Available at: http://www.maps.org/research/lsd/swisslsd/IB_LSD.pdf (accessed 1 June 2014).
108. Jiang W. Zhang Y. Xiao L. Van Cleemput J. Ji S.P. Bai G. et al. (2005) Cannabinoids Promote Embryonic and Adult Hippocampus Neurogenesis and Produce Anxiolytic– and Antidepressant–Like Effects. J Clin Invest 115: 3104–3116.
109. Johnson M. Richards W. Griffiths R. (2008) Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol 22: 603–620.
110. Jovel A. Felthous A. Bhattacharyya A. (2013) Delirium Due to Intoxication from the Novel Synthetic Tryptamine 5–Meo–Dalt. J Forensic Sci 59: 844–846.
111. Kalechstein A.D. De La Garza R. Mahoney J.J. Fantegrossi W.E. Newton T.F. (2007) Mdma Use and Neurocognition: A Meta–Analytic Review. Psychopharmacology 189: 531–537.
112. Kalir A. Edery H. Pelah Z. Balderman D. Porath G. (1969) 1–Phenylcycloalkylamine derivatives. II. Synthesis and pharmacological activity. J Med Chem 12: 473–477.
113. Karila L. Roux P. Rolland B. Benyamina A. Reynaud M. Aubin H.-J. et al. (2013) Acute and Long–Term Effects of Cannabis Use: A Review. Curr Pharm Des 20: 4112–8
114. Kattimani S. Bharadwaj B. (2013) Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J 2: 100–108.
115. Kehr J. Ichinose F. Yoshitake S. Goiny M. Sievertsson T. Nyberg F. et al. (2011) Mephedrone, Compared with Mdma (Ecstasy) and Amphetamine, Rapidly Increases Both Dopamine and 5–HT Levels in Nucleus Accumbens of Awake Rats. Br J Pharmacol 164: 1949–1958.
116. Kilpatrick Z.P. Bard Ermentrout G. (2012) Hallucinogen Persisting Perception Disorder in Neuronal Networks with Adaptation. J Comput Neurosci 32: 25–53.
117. King L. A. Nutt D. J. (2014). Deaths from ‘legal highs’: a problem of definitions. Lancet 9921: 952.
118. Koenig X. Kovar M. Boehm S. Sandtner W. Hilber K. (2014) Anti–Addiction Drug Ibogaine Inhibits Herg Channels: A Cardiac Arrhythmia Risk. Addict Biol 19: 237–239.
119. Koob G.F. Volkow N.D. (2010) Neurocircuitry of Addiction. Neuropsychopharmacology 35: 217–238.
120. Kousik S.M. Napier T.C. Carvey P.M. (2012) The Effects of Psychostimulant Drugs on Blood Brain Barrier Function and Neuroinflammation. Front Pharmacol 3: 121
121. Krebs T. S. Johansen P. Ø. (2012a) Methodological weaknesses in non–randomized studies of ecstasy (MDMA) use: a cautionary note to readers and reviewers. Neuropsychopharmacology 4 1070–1; author reply 1072–3.
122. Krebs T.S. Johansen P.-Ø. (2012b) Lysergic Acid Diethylamide (LSD) for Alcoholism: Meta–Analysis of Randomized Controlled Trials. J Psychopharmacol 26: 994–1002.
123. Krebs T.S. Johansen P.-Ø. (2013) Psychedelics and Mental Health: A Population Study. PLoS ONE 8: e63972.
124. Kriikku P. Wilhelm L. Schwarz O. Rintatalo J. (2011) New Designer Drug of Abuse: 3,4–Methylenedioxypyrovalerone (Mdpv). Findings from Apprehended Drivers in Finland. Forensic Sci Int 210: 195–200.
125. Krystal J. H. Karper L. P. Seibyl J. P. Freeman G. K. Delaney R. Bremer J.D. et al. (1994). Subanesthetic effects of the noncompetetive NMDA antagonist ketamine in humans. Arch Gen Psychiatry 51: 199–214.
126. Kuepper R. Ceccarini J. Lataster J. Van Os J. Van Kroonenburgh M. Van Gerven J.M.A. et al. (2013) Delta–9–Tetrahydrocannabinol–Induced Dopamine Release as a Function of Psychosis Risk: 18f–Fallypride Positron Emission Tomography Study. PLoS ONE 8.
127. Kursanov N. (1907). Phenyl derivatives of naphthenes, second paper, some derivatives of phenylcyclohexane. Zh Russ Fiz–Khim O–va 38, 1295.
128. Kuypers K.P.C. Ramaekers J.G. (2007) Acute Dose of MDMA (75 Mg) Impairs Spatial Memory for Location but Leaves Contextual Processing of Visuospatial Information Unaffected. Psychopharmacology (Berl) 189: 557–563.
129. Larson M.K. Walker E.F. Compton M.T. (2010) Early Signs, Diagnosis and Therapeutics of the Prodromal Phase of Schizophrenia and Related Psychotic Disorders. Expert Rev Neurother 10: 1347–1359.
130. Lawn W. Barratt M. Williams M. Horne A. Winstock A. (2014) The Nbome Hallucinogenic Drug Series: Patterns of Use, Characteristics of Users and Self–Reported Effects in a Large International Sample. J Psychopharmacol 28: 780–788.
131. Levy L. Cameron D. E. Aitken R. C. (1960). Observation on two psychotomimetic drugs of piperidine derivation—CI 395 (sernyl) and CI 400. Am J Psychiatry 116, 843–844.
132. Leweke F.M. Piomelli D. Pahlisch F. Muhl D. Gerth C.W. Hoyer C. et al. (2012) Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia. Transl Psychiatry 2: e94
133. Li N. Lee B. Liu R.-J. Banasr M. Dwyer J.M. Iwata M. et al. (2010) Mtor–Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of Nmda Antagonists. Science 329: 959–964.
134. Liechti M.E. Saur M.R. Gamma A. Hell D. Vollenweider F.X. (2000) Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT(2) Antagonist Ketanserin in Healthy Humans. Neuropsychopharmacology 4: 396–404.
135. Liechti M.E. Vollenweider F.X. (2000) Acute Psychological and Physiological Effects of MDMA (‘Ecstasy’) after Haloperidol Pretreatment in Healthy Humans. Eur Neuropsychopharmacol 10: 289–295.
136. Liechti M.E. Vollenweider F.X. (2001) Which Neuroreceptors Mediate the Subjective Effects of MDMA in Humans? A Summary of Mechanistic Studies. Hum Psychopharmacol 16: 589–598.
137. Liechti M.E. Gamma A. Vollenweider F.X. (2001) Gender Differences in the Subjective Effects of MDMA. Psychopharmacology 154: 161–168.
138. Lim D.K. (2003) Ketamine Associated Psychedelic Effects and Dependence. Singapore Med J 1: 31–34.
139. Lindefors N. Barati S. O'Connor W.T. (1997) Differential Effects of Single and Repeated Ketamine Administration on Dopamine, Serotonin and GABA Transmission in Rat Medial Prefrontal Cortex. Brain Res 759: 205–212.
140. Lindemann L. Meyer C.A. Jeanneau K. Bradaia A. Ozmen L. Bluethmann H. et al. (2008) Trace Amine–Associated Receptor 1 Modulates Dopaminergic Activity. J Pharmacol Exp Ther 324: 948–956.
141. Lindigkeit R. Boehme A. Eiserloh I. Luebbecke M. Wiggermann M. Ernst L. et al. (2009) Spice: A Never Ending Story? Forensic Sci Int 191: 58–63.
142. Loix S. De Kock M. Henin P. (2011) The Anti–Inflammatory Effects of Ketamine: State of the Art. Acta Anaesthesiol Belg 62: 47–58.
143. Lüscher C. Ungless M.A. (2006) The Mechanistic Classification of Addictive Drugs. PLoS Med 3: e437.
144. Malhotra A.K. Pinals D.A. Adler C.M. Elman I. Clifton A. Pickar D. et al. (1997) Ketamine–Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic–Free Schizophrenics. Neuropsychopharmacology 17: 141–150.
145. Martin–Santos R. A. Crippa J. Batalla A. Bhattacharyya S. Atakan Z. Borgwardt S. et al. (2012) Acute Effects of a Single, Oral Dose of D9–Tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers. Curr Pharm Des 18: 4966–4979.
146. Maskell P.D. De Paoli G. Nitin Seetohul L. Pounder D.J. (2012) Phenazepam: The Drug That Came in from the Cold. J Forensic Leg Med 19: 122–125.
147. Maskell P.D. De Paoli G. Seneviratne C. Pounder D.J. (2011) Mephedrone (4–Methylmethcathinone)–Related Deaths. J Anal Toxicol 35: 188–191.
148. McCann U.D. Ricaurte G.A. (2004) Amphetamine Neurotoxicity: Accomplishments and Remaining Challenges. Neurosci Biobehav Rev 27: 821–826.
149. Menzies E.L. Hudson S.C. Dargan P.I. Parkin M.C. Wood D.M. Kicman A.T. (2014) Characterizing Metabolites and Potential Metabolic Pathways for the Novel Psychoactive Substance Methoxetamine. Drug Test Anal 6: 506–515.
150. Meyer M.R. Bach M. Welter J. Bovens M. Turcant A. Maurer H.H. (2013) Ketamine–Derived Designer Drug Methoxetamine: Metabolism Including Isoenzyme Kinetics and Toxicological Detectability Using GC–MS and LC–(HR–)MS N. Anal Bioanal Chem 405: 6307–6321.
151. Miller G.M. (2011) The Emerging Role of Trace Amine–Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity. J Neurochem 116: 164–176.
152. Miotto K. Striebel J. Cho A.K. Wang C. (2013) Clinical and Pharmacological Aspects of Bath Salt Use: A Review of the Literature and Case Reports. Drug Alcohol Depend 132: 1–12.
153. Mithoefer M. C. M. Wagner M. M. T. Mithoefer A. A. T. Jerome L. Martin S. F. Yazar–Klosinski B. et al. (2012). Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4–methylenedioxymethamphetamine–assisted psychotherapy: a prospective long–term follow–up study. J Psychopharmacol 27 28–39.
154. Mithoefer M. Jerome L. Doblin R. (2003) MDMA (‘Ecstasy’) and Neurotoxicity. Science 300: 1504–5.
155. Mithoefer M.C. Wagner M.T. Mithoefer A.T. Jerome L. Doblin R. (2011) The Safety and Efficacy of MDMA–Assisted Psychotherapy in Subjects with Chronic, Treatment–Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study. J Psychopharmacol 25: 439–452.
156. Moghaddam B. Adams B. Verma A. Daly D. (1997) Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex. J Neurosci 17(8): 2921–2927.
157. Moore T.H. Zammit S. Lingford–Hughes A. Barnes T.R. Jones P.B. Burke M. et al. (2007) Cannabis Use and Risk of Psychotic or Affective Mental Health Outcomes: A Systematic Review. Lancet 370: 319–28.
158. Moosmann B. Huppertz L.M. Hutter M. Buchwald A. Ferlaino S. Auwärter V. (2013a) Detection and Identification of the Designer Benzodiazepine Flubromazepam and Preliminary Data on Its Metabolism and Pharmacokinetics. J Mass Spectrom 48: 1150–1159.
159. Moosmann B. Hutter M. Huppertz L.M. Ferlaino S. Redlingshöfer L. Auwärter V. (2013b) Characterization of the Designer Benzodiazepine Pyrazolam and Its Detectability in Human Serum and Urine. Forensic Toxicol 31: 263–271.
160. Moretti S. Castelli M. Franchi S. Raggi M. Mercolini L. Protti M. et al. (2014) Δ9–Tetrahydrocannabinol–induced anti–inflammatory responses in adolescent mice switch to proinflammatory in adulthood. J Leukoc Biol 96: 523–534.
161. Morgan C.J.A. Curran H.V. (2006) Acute and Chronic Effects of Ketamine Upon Human Memory: A Review. Psychopharmacology 188: 408–24.
162. Morgan C.J.A. Monaghan L. Curran H.V. (2004) Beyond the K–Hole: A 3–Year Longitudinal Investigation of the Cognitive and Subjective Effects of Ketamine in Recreational Users Who Have Substantially Reduced Their Use of the Drug. Addiction 99: 1450–1461.
163. Morgan C.J.A. Muetzelfeldt L. Curran H.V. (2009) Ketamine Use, Cognition and Psychological Wellbeing: A Comparison of Frequent, Infrequent and Ex–Users with Polydrug and Non–Using Controls. Addiction 104: 77–87.
164. Morgan C.J.A. Muetzelfeldt L. Curran H.V. (2010) Consequences of Chronic Ketamine Self–Administration Upon Neurocognitive Function and Psychological Wellbeing: A 1–Year Longitudinal Study. Addiction 105: 121–133.
165. Morgan C.J.A. Rees H. Curran H.V. (2008) Attentional Bias to Incentive Stimuli in Frequent Ketamine Users. Psychol Med 38: 1331–1340.
166. Morris H. Wallach J. (2014) From PCP to MXE: A Comprehensive Review of the Non–Medical Use of Dissociative Drugs. Drug Test Anal 6: 614–32.
167. Motbey C.P. Clemens K.J. Apetz N. Winstock A.R. Ramsey J. Li K.M. et al. (2013) High Levels of Intravenous Mephedrone (4–Methylmethcathinone) Self–Administration in Rats: Neural Consequences and Comparison with Methamphetamine. J Psychopharmacol 27: 823–836.
168. Muetzelfeldt L. Kamboj S.K. Rees H. Taylor J. Morgan C.J.A. Curran H.V. (2008) Journey through the K–Hole: Phenomenological Aspects of Ketamine Use. Drug Alcohol Depend 95: 219–229.
169. Murray B.L. Murphy C.M. Beuhler M.C. (2012) Death Following Recreational Use of Designer Drug ‘Bath Salts’ Containing 3,4–Methylenedioxypyrovalerone (Mdpv). J Med Toxicol 8: 69–75.
170. Murray R.M. Paparelli A. Morrison P.D. Marconi A. Di Forti M. (2013) What Can We Learn About Schizophrenia from Studying the Human Model, Drug–Induced Psychosis? Am J Med Genet B Neuropsychiatr Genet 162: 661–670.
171. Nagai F. Nonaka R. Satoh Hisashi Kamimura K. (2007) The Effects of Non–Medically Used Psychoactive Drugs on Monoamine Neurotransmission in Rat Brain. Eur J Pharmacol 559: 132–137.
172. Ng S.H. Tse M.L. Ng H.W. Lau F.L. (2010) Emergency Department Presentation of Ketamine Abusers in Hong Kong: A Review of 233 Cases. Hong Kong Med J 16(1): 6–11.
173. Nichols D. E. (1986). Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 4 305–313.
174. Nichols D.E. (2004) Hallucinogens. Pharmacol Ther 101: 131–181.
175. Nikolaou P. Papoutsis I. Stefanidou M. Spiliopoulou C. Athanaselis S. (2014) 2C–I–Nbome, an ‘N–bomb’ That Kills with ‘Smiles’. Toxicological and Legislative Aspects. Drug Chem Toxicol 0545: 1–7.
176. Noguchi T.T. Nakamura G.R. (1978) Phencyclidine–Related Deaths in Los Angeles County, 1976. J Forensic Sci 23: 503–507.
177. Nulsen C.E. Fox A.M. Hammond G.R. (2010) Differential Effects of Ecstasy on Short–Term and Working Memory: A Meta–Analysis. Neuropsychol Rev 20: 21–32.
178. Nutt D.J. King L.A. Phillips L.D. (2010) Drug Harms in the UK: A Multicriteria Decision Analysis. Lancet 376: 1558–1565.
179. O'Daly O. G. Joyce D. Tracy D. K. Stephan K. E. Murray R. M. Shergill S. (2014a) Amphetamine sensitisation and memory in healthy human volunteers: A functional magnetic resonance imaging study. J Psychopharmacol 28: 857–65.
180. O'Daly O.G. Joyce D. Tracy D.K. Azim A. Stephan K.E. Murray R.M. et al. (2014b) Amphetamine Sensitization Alters Reward Processing in the Human Striatum and Amygdala. PLoS ONE 9: e93955.
181. Oehen P. Traber R. Widmer V. Schnyder U. (2012) A Randomized, Controlled Pilot Study of MDMA (±3,4–Methylenedioxymethamphetamine)–Assisted Psychotherapy for Treatment of Resistant, Chronic Post–Traumatic Stress Disorder (PTSD). J Psychopharmacol 27: 40–52.
182. Olives T. D. Orozco B. S. Stellpflug S. J. (2012). Bath Salts: the Ivory Wave of trouble. West J Emerg Med 13: 58–62.
183. Pacher P. Bátkai S. Kunos G. (2006) The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol Rev 58: 389–462.
184. Papanti D. Orsolini L. Francesconi G. Schifano F. (2014) ‘Noids’ in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. Adv Dual Diagn 7: 137–148.
185. Papanti D. Schifano F. Botteon G. Bertossi F. Mannix J. Vidoni D. et al. (2013) ‘Spiceophrenia’: A Systematic Overview of ‘Spice’–Related Psychopathological Issues and a Case Report. Hum Psychopharmacol 28: 379–389.
186. Park B. McPartland J.M. Glass M. (2004) Cannabis, Cannabinoids and Reproduction. Prostaglandins Leukot Essent Fatty Acids 70: 189–197.
187. Parrott A.C. (2012) MDMA and 5–HT Neurotoxicity: The Empirical Evidence for Its Adverse Effects in Humans – No Need for Translation. Br J Pharmacol 166: 1518–1520.
188. Parrott A.C. (2013) MDMA, Serotonergic Neurotoxicity and the Diverse Functional Deficits of Recreational ‘Ecstasy’ Users. Neurosci Biobehav Rev 37: 1466–1484.
189. Passie T. Seifert J. Schneider U. Emrich H.M. (2002) The Pharmacology of Psilocybin. Addict Biol 7: 357–364.
190. Penn E. Tracy D.K. (2012) The Drugs Don't Work? Antidepressants and the Current and Future Pharmacological Management of Depression, Ther Adv Psychopharmacol 2: 179–88.
191. Pertwee R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Delta9–Tetrahydrocannabinol, Cannabidiol and Delta9–Tetrahydrocannabivarin. Br J Pharmacol 153: 199–215.
192. Pochwat B. Pałucha–Poniewiera A. Szewczyk B. Pilc A. Nowak G. (2014) Nmda Antagonists under Investigation for the Treatment of Major Depressive Disorder. Expert Opin Investig Drugs: 1–12.
193. Pompili M. Serafini G. Innamorati M. Venturini P. Fusar–Poli P. Sher L. et al. (2013) Agomelatine, a Novel Intriguing Antidepressant Option Enhancing Neuroplasticity: A Critical Review. World J Biol Psychiatry 14: 412–431.
194. Pradhan S.N. (1984) Phencyclidine (Pcp): Some Human Studies. Neurosci Biobehav Rev 8: 493–501.
195. Presley B.C. Jansen–Varnum S.A. Logan B.K. (2014) Analysis of Synthetic Cannabinoids in Botanical Material: A Review of Analytical Methods and Findings. Forensic Sci Rev: 27–46.
196. Presti D. E. Nichols D. E. (2004) Biochemistry and neuropharmacology of psilocybin mushrooms. In: Metzner R. Darling D. (eds), Teonanacatl. El Verano, CA: Four Trees, pp 89–108.
197. Psychoyos D. Vinod K.Y. Cao J. Xie S. Hyson R.L. Wlodarczyk B. et al. (2012) Cannabinoid Receptor 1 Signaling in Embryo Neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95: 137–150.
198. Raison C.L. Demetrashvili M. Capuron L. Miller A.H. (2005) Neuropsychiatric Adverse Effects of Interferon–Alpha: Recognition and Management. CNS Drugs 19: 105–123.
199. Robinson T. E. Berridge K. C. (1993). The neural basis of drug craving: an incentive–sensitization theory of addiction. Brain Res Rev 18: 247–91.
200. Robson M.J. Elliott M. Seminerio M.J. Matsumoto R.R. (2012) Evaluation of Sigma (σ) Receptors in the Antidepressant–Like Effects of Ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22: 308–317.
201. Romer D. (2010) Adolescent Risk Taking, Impulsivity and Brain Development: Implications for Prevention. Dev Psychobiol 52: 263–276.
202. Roth B.L. Gibbons S. Arunotayanun W. Huang X.P. Setola V. Treble R. et al. (2013) The Ketamine Analogue Methoxetamine and 3– and 4–Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor. PLoS ONE 8: e59334.
203. Rothman R.B. Baumann M.H. (2006) Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine–Type Drugs. Ann N Y Acad Sci 1074: 245–60.
204. Schenk S. (2009) MDMA Self–Administration in Laboratory Animals: A Summary of the Literature and Proposal for Future Research. Neuropsychobiology 60: 130–136.
205. Schifano F. (2014). Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28: 491–6.
206. Schifano F. Corkery J. Oyefeso A. Tonia T. Ghodse A. H. (2008). Trapped in the ‘‘K–hole’’ overview of deaths associated with ketamine misuse in the UK (1993–2006). J Clin Psychopharmacol 28: 114–116.
207. Schifano F. Deluca P. Baldacchino A. Peltoniemi T. Scherbaum N. Torrens M. et al. (2006) Drugs on the Web; the Psychonaut 2002 Eu Project. Prog Neuropsychopharmacol Biol Psychiatry 30: 640–646.
208. Schmidt M.M. Sharma A. Schifano F. Feinmann C. (2011) ‘Legal Highs’ on the Net–Evaluation of UK–Based Websites, Products and Product Information. Forensic Sci Int 206: 92–97.
209. Schramm-Sapyta N.L. Cha Y.M. Chaudhry S. Wilson W.A. Swartzwelder H.S. Kuhn C.M. (2007) Differential Anxiogenic, Aversive and Locomotor Effects of THC in Adolescent and Adult Rats. Psychopharmacology 191: 867–877.
210. Schwope D.M. Bosker W.M. Ramaekers J.G. Gorelick D.A. Huestis M.A. (2012) Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9–Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. J Anal Toxicol 36: 405–412.
211. Scott J.C. Woods S.P. Matt G.E. Meyer R.A. Heaton R.K. Atkinson J.H. et al. (2007) Neurocognitive Effects of Methamphetamine: A Critical Review and Meta–Analysis. Neuropsychol Rev 17(3): 275–97.
212. Seely K.A. Patton A.L. Moran C.L. Womack M.L. Prather P.L. Fantegrossi W.E. et al. (2013) Forensic Investigation of K2, Spice and ‘Bath Salt’ Commercial Preparations: A Three–Year Study of New Designer Drug Products Containing Synthetic Cannabinoid, Stimulant and Hallucinogenic Compounds. Forensic Sci Int 233: 416–422.
213. Shahani R. Streutker C. Dickson B. Stewart R.J. (2007) Ketamine–Associated Ulcerative Cystitis: A New Clinical Entity. Urology 69: 810–812.
214. Shoptaw S.J. Kao U. Ling W. (2009) Treatment for Amphetamine Psychosis. Cochrane Database Syst Rev 1: CD003026.
215. Shulgin A. Shulgin A. (1997). PIHKAL: A Chemical Love Story. Berkeley, CA: Transform Press.
216. Silvestri C. Di Marzo V. (2012) Second Generation CB1 Receptor Blockers and Other Inhibitors of Peripheral Endocannabinoid Overactivity and the Rationale of Their Use against Metabolic Disorders. Expert Opin Investig Drugs 21: 1309–1322.
217. Simmler L.D. Buser T.A. Donzelli M. Schramm Y. Dieu L.H. Huwyler J. et al. (2013) Pharmacological Characterization of Designer Cathinones in vitro. Br J Pharmacol 168: 458–470.
218. Simmler L.D. Rickli A. Hoener M.C. Liechti M.E. (2014a) Monoamine Transporter and Receptor Interaction Profiles of a New Series of Designer Cathinones. Neuropharmacology 79: 152–160.
219. Simmler L.D. Rickli A. Schramm Y. Hoener M.C. Liechti M.E. (2014b) Pharmacological Profiles of Aminoindanes, Piperazines and Pipradrol Derivatives. Biochem Pharmacol 88: 237–244.
220. Soussan C. Kjellgren A. (2014). The flip side of ‘Spice’: The adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. Nord Stud Alcohol Drugs 31: 123–224.
221. Spaderna M. Addy P.H. D'Souza D.C. (2013) Spicing Things Up: Synthetic Cannabinoids. Psychopharmacology 228: 525–540.
222. Steinpreis R.E. (1996) The Behavioral and Neurochemical Effects of Phencyclidine in Humans and Animals: Some Implications for Modeling Psychosis. Behav Brain Res 74: 45–55.
223. Sternbach L.H. Fryer R.I. Metlesics W. Reeder E. Sach G. Saucy G. Stempel A. (1962) Quinazolines and 1,4–benzodiazepines.VI.1a halo–, methyl– and methoxy–substituted 1,3–dihydro–5–phenyl–2H–1,4–benzodiazepin–2–ones1b, c. J Org Chem 27 3788.
224. Stewart C.E. (2001). Ketamine as a Street Drug. Emerg Med Serv 30(11): 30, 32, 34 passim.
225. Strassman R.J. (1995) Human Psychopharmacology of N, N–Dimethyltryptamine. Behav Brain Res 73: 121–4.
226. Studerus E. Gamma A. Vollenweider F.X. (2010) Psychometric Evaluation of the Altered States of Consciousness Rating Scale (Oav). PLoS ONE 5: e12412.
227. Suárez-Pinilla P. López-Gil J. Crespo-Facorro B. (2014) Immune System: A Possible Nexus between Cannabinoids and Psychosis. Brain Behav Immun 40: 269–282.
228. Sun X. Dey S.K. (2012) Endocannabinoid Signaling in Female Reproduction. ACS Chem Neurosci 3: 349–55.
229. Tang M.H.Y. Ching C.K. Tsui M.S.H. Chu F.K.C. Mak T.W.L. (2014) Two Cases of Severe Intoxication Associated with Analytically Confirmed Use of the Novel Psychoactive Substances 25B–Nbome and 25C–Nbome. Clin Toxicol 52: 561–565.
230. Tracy D.K. Shergill S.S. (2013) Mechanisms Underlying Auditory Hallucinations–Understanding Perception without Stimulus. Brain Sci 3: 642–669.
231. Traynelis S.F. Wollmuth L.P. McBain C.J. Menniti F.S. Vance K.M. Ogden K.K. et al. (2010) Glutamate Receptor Ion Channels: Structure, Regulation and Function. Pharmacol Rev 62: 405–496.
232. Turillazzi E. Riezzo I. Neri M. Bello S. Fineschi V. (2010) MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings. Curr Pharm Biotechnol 11: 500–509.
233. UNODC (2012) World Drug Report 2012. Joost 2012: 316.
234. Van Amsterdam J. Opperhuizen A. van den Brink W. (2011) Harm Potential of Magic Mushroom Use: A Review. Regul Toxicol Pharmacol 59: 423–429.
235. Vento A.E. Schifano F. Gentilli F. Pompei F. Corkery J.M. Kotzalidis G.D. et al. (2013) Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Ann Ist Super Sanita 49: 402–405.
236. Vollenweider F.X. Maguire R.P. Leenders K.L. Mathys K. Angst J. (1998a) Effects of High Amphetamine Dose on Mood and Cerebral Glucose Metabolism in Normal Volunteers Using Positron Emission Tomography (PET). Psychiatry Res 83: 149–162.
237. Vollenweider F.X. Vollenweider–Scherpenhuyzen M.F. Bäbler A. Vogel H. Hell D. (1998b) Psilocybin Induces Schizophrenia–Like Psychosis in Humans Via a Serotonin–2 Agonist Action. Neuroreport 9: 3897–3902.
238. Vollenweider F.X. Vontobel P. Øye I. Hell D. Leenders K.L. (2000) Effects of (S)–Ketamine on Striatal Dopamine: A [11c]Raclopride PET Study of a Model Psychosis in Humans. J Psychiatr Res 34: 35–43.
239. Völlm B.A. De Araujo I.E. Cowen P.J. Rolls E.T. Kringelbach M.L. Smith K.A. et al. (2004) Methamphetamine Activates Reward Circuitry in Drug Naïve Human Subjects. Neuropsychopharmacology 29: 1715–1722.
240. Wacker D. Wang C. Katritch V. Han G.W. Huang X.-P. Vardy E. et al. (2013) Structural Features for Functional Selectivity at Serotonin Receptors. Science 340: 615–619.
241. White T.L. Lejuez C.W. De Wit H. (2007) Personality and Gender Differences in Effects of D–Amphetamine on Risk Taking. Exp Clin Psychopharmacol 15: 599–609.
242. White T.L. Lott D.C. De Wit H. (2006) Personality and the Subjective Effects of Acute Amphetamine in Healthy Volunteers. Neuropsychopharmacology 31: 1064–1074.
243. Wikström M. Thelander G. Dahlgren M. Kronstrand R. (2013) An Accidental Fatal Intoxication with Methoxetamine. J Anal Toxicol 37: 43–46.
244. Wiley J.L. Lefever T.W. Cortes R.A. Marusich J.A. (2014) Cross–Substitution of Δ9–Tetrahydrocannabinol and JWH–018 in Drug Discrimination in Rats. Pharmacol Biochem Behav 124: 123–128.
245. Winstock A.R. Barratt M.J. (2013) The 12–Month Prevalence and Nature of Adverse Experiences Resulting in Emergency Medical Presentations Associated with the Use of Synthetic Cannabinoid Products. Human Psychopharmacol 28: 390–393.
246. Winstock A.R. Mitcheson L.R. Deluca P. Davey Z. Corazza O. Schifano F. (2011a) Mephedrone, New Kid for the Chop? Addiction 106: 154–161.
247. Winstock A. Mitcheson L. Ramsey J. Davies S. Puchnarewicz M. Marsden J. (2011b) Mephedrone: Use, Subjective Effects and Health Risks. Addiction 106: 1991–1996.
248. Winstock A.R. Mitcheson L. Gillatt D.A. Cottrell A.M. (2012) The Prevalence and Natural History of Urinary Symptoms among Recreational Ketamine Users. BJU Int 11: 1762–1766.
249. Wong S.W. Lee K.F. Wong J. Ng W.W.C. Cheung Y.S. Lai P.B.S. (2009) Dilated Common Bile Ducts Mimicking Choledochal Cysts in Ketamine Abusers. Hong Kong Med J 15: 53–56.
250. Xie Z. Miller G.M. (2009) Trace Amine–Associated Receptor 1 as a Monoaminergic Modulator in Brain. Biochem Pharmacol 78: 1095–1104.
251. Young A. C. Schwarz E. S. Velez L. I. Gardner M. (2012). Two cases of disseminated intravascular coagulation due to ‘bath salts’ resulting in fatalities, with laboratory confirmation. Am J Emerg Med 31: 445.e3–5.
252. Zarate C. A. Jr Singh J. B. Carlton P. J. Brutsche N. E. Ameli R. Luckenbaugh D. A. et al. (2006) A randomized trial of an N–methyl–D–aspartate antagonist in treatment–resistant major depression. Arch Gen Psychiatry 63: 856–864.
253. Zimmermann U.S. Winkelmann P.R. Pilhatsch M. Nees J.A. Spanagel R. Schulz K. (2009) Withdrawal Phenomena and Dependence Syndrome after the Consumption of ‘Spice Gold’. Deutsches Arzteblatt international 106: 464–467.
254. Zuba D. Sekuła K. Buczek A. (2013) 25c–Nbome – New Potent Hallucinogenic Substance Identified on the Drug Market. Forensic Sci Int 227: 7–14.